(Source: Neothetics Inc) SAN DIEGO, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the third quarter 2015. 'We have been very productive the past few quarters as we have completed enrollment for our pivotal Phase 3 studies in early September,' said George Mahaffey, president and chief executive officer of Neothetics. 'We are tightening our guidance regarding the release of our top-line results for the AbCONTOUR1 and AbCONTOUR2 trials and expect to release these top-line results in December.' Third Quarter 2015...
↧